5 Key Takeaways

• 1

  Low-dose rivaroxaban did not significantly reduce left ventricular thrombus in anterior STEMI patients compared to dual antiplatelet therapy alone.

• 2

  In the APERITIF trial, left ventricular thrombus was found in 14% of patients on rivaroxaban and 17% on dual antiplatelet therapy.

• 3

  The trial involved 560 patients and did not meet its primary endpoint, with similar baseline characteristics across treatment groups.

• 4

  Bleeding events were more frequent in the rivaroxaban group, with 18% experiencing any bleeding compared to 9% in the dual therapy group.

• 5

  The study's open-label design and fewer thrombus events than expected limited its statistical power, necessitating cautious interpretation of results.